narsoplimab

omeros kidney disease drug, omeros phase 3 trial, omeros stock price, oms721 igA nephropathy, omeros trial termination, omeros news, omeros drug failure,

Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets

Anika Sharma

In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...